What the research reports on peptides and tendon repair

Tendon heals slowly, and the reason is plumbing. Tendon is dense collagen with a thin blood supply, so the cells that rebuild it arrive late and in small numbers. Almost every peptide studied for tendon repair is aimed at that one bottleneck: get more blood, and more of the right cells, to the injury sooner.

This is what the published work actually measured, and, just as importantly, where it stops.

What these studies are measuring

Tendon research does not measure whether someone feels better. It measures tissue. The recurring endpoints are the density of new blood vessels at the injury site, how quickly fibroblasts migrate into the gap, how much new collagen is laid down and in what orientation, and the mechanical load a repaired tendon takes before it fails again.

Almost all of it is animal work, usually a rat Achilles tendon that has been transected or detached, then assessed over two to four weeks. Keep that in mind for everything below. A result in a rat Achilles model is a real result about rat Achilles tendons.

BPC-157: the vascular argument

BPC-157 is a pentadecapeptide, a fifteen amino acid sequence derived from a protein found in gastric juice. It is the single most studied compound in this space.

The most cited tendon result is Krivic and colleagues in the Journal of Orthopaedic Research, working with Sikiric's group. They surgically detached the Achilles tendon from bone in rats, a defect that does not heal on its own, and reported that BPC-157 recovered tendon-to-bone healing. The same group reported accelerated healing of transected rat Achilles tendon, alongside in vitro work showing stimulated tendocyte growth.

The proposed mechanism is vascular, and it is specific. BPC-157 upregulates vascular endothelial growth factor receptor 2 and activates the VEGFR2-Akt-eNOS signalling cascade, which is the pathway that drives new vessels into damaged tissue. Given that tendon's poor blood supply is the rate-limiting step in its repair, a compound acting on angiogenesis is a coherent thing to study here rather than an arbitrary one.

The limit is worth stating plainly. A 2025 systematic review found no completed controlled human efficacy trials for BPC-157. Not inconclusive trials. None completed. Any page presenting a human tendon outcome for BPC-157 is presenting something that has not been run.

TB-500 and the actin mechanism

TB-500 is a synthetic fragment of thymosin beta-4, an actin-binding protein.

Its mechanism is mechanical rather than vascular. Thymosin beta-4 binds monomeric G-actin and holds a pool of it in reserve, available for rapid polymerisation when a cell needs to move. Cell migration is the rate limiter in the early phase of repair, when fibroblasts have to physically reach the wound before they can build anything.

A 2026 scoping review in Applied Sciences collected the tissue healing and musculoskeletal literature on thymosin beta-4 and TB-500. The pattern across it is consistent: animal and cell-culture work supports a role in cell migration, angiogenesis and reduced scar formation, replicated by independent groups across several injury models, with human evidence thin.

BPC-157 and TB-500 are usually studied together rather than separately, and the reasoning is that they address different stages of the same process. One brings the blood supply, the other brings the cells. That is also why they are supplied as a combination rather than as two purchases: the BPC-157 and TB-500 20mg pen carries both in one lot with one certificate.

GHK-Cu: collagen and the matrix

GHK-Cu is a copper-binding tripeptide isolated from human plasma. Where BPC-157 and TB-500 act on supply lines, GHK-Cu appears in the literature on what gets built afterwards.

Studies on dermal fibroblasts report that it stimulates collagen and glycosaminoglycan synthesis and upregulates tissue inhibitor of metalloproteinases, a protein that slows the breakdown of the extracellular matrix. Tendon and skin are both collagen-and-matrix tissues, which is why dermal findings keep getting cited in connective tissue discussions. That is an inference across tissue types, not a tendon result, and it should be read as one.

The Glow Stack exists because of that division of labour: it combines BPC-157, TB-500 and GHK-Cu rather than treating them as alternatives to each other.

Why the growth hormone compounds keep appearing

CJC-1295, ipamorelin and tesamorelin are not tendon compounds. They show up in these reviews through one link: IGF-1 is a driver of collagen synthesis in connective tissue.

CJC-1295 is a GHRH analogue with a drug affinity complex that extends its half-life. The human data comes from Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism, a randomised, double-blind, placebo-controlled study in healthy adults. A single injection produced dose-dependent increases in IGF-1 of roughly 1.5 to 3 fold sustained for nine to eleven days, with growth hormone rising 2 to 10 fold for six days or more. After repeated doses, IGF-1 stayed above baseline for as long as 28 days.

That is a real human pharmacodynamic result, and it is worth being precise about what it is: a measurement of hormone levels, not of tendon healing. Nobody has connected that curve to a repaired tendon in a controlled human study.

Tesamorelin, a longer GHRH analogue, carries the most clinical weight of the three, though its trials are metabolic rather than musculoskeletal. The pivotal work by Falutz and colleagues in the New England Journal of Medicine, and later Stanley and colleagues in JAMA, studied HIV-associated lipodystrophy and reported roughly a 15 to 18 percent relative reduction in visceral adipose tissue at 26 weeks.

How to check what you are actually buying

The compounds above are only meaningful if the material in the container is the material on the label, and at the stated amount.

Two numbers on a certificate of analysis answer different questions, and they are routinely confused. Purity is the fraction of the peptide-related material that is the target compound. Content is how much target compound is physically in the container. A vial can report excellent purity and still hold less peptide than the label says, because residual water, counterions and salts do not appear as impurity peaks. Our longer guide to reading a certificate of analysis covers the rest of the fields.

Every ReadyPep lot is tested by an independent laboratory and the certificate for that specific lot is published, with the lot number on the pen matching the lot number on the document.

ReadyPep supplies materials for laboratory research use only, under our research use policy. Nothing above describes preparation or use in humans, and none of the studies cited here were conducted to answer that question.